Skip to main content

IntegraGen Receives $2.4M from French Investment Firm

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said on Thursday it has received €2 million ($2.4 million) in financing from funds managed by French private investment firm A Plus Finance.

The funds will go toward the continued development of genetic tests for colorectal cancer and liver cancer, Integragen, also based in France, said, and to accelerate R&D and commercialization efforts directed at molecular diagnostics for autism.

IntegraGen was founded in 2000 and specializes in identifying genetic biomarkers for the development of molecular diagnostics with a focus on autism and oncology. In April, the company launched its Arisk Risk Assessment Test, a genetic screening tool for autism.

Its US affiliate, IntegraGen Inc., is based in Cambridge, Mass.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.